bexarotene has been researched along with Pituitary ACTH Hypersecretion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, G; Lv, T; Ren, S; Sun, L; Wang, J; Yu, H | 1 |
| Chen, Y; Li, G; Lu, J; Shen, D; Wang, H; Wang, M; Xia, L; Xie, D; Xue, D; Zhang, Y | 1 |
2 other study(ies) available for bexarotene and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Bexarotene combined with lapatinib for the treatment of Cushing's disease: evidence based on drug repositioning and experimental confirmation.
Topics: Adrenocorticotropic Hormone; Animals; Bexarotene; Drug Combinations; Drug Repositioning; Humans; Lapatinib; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Protein Interaction Maps; Retinoid X Receptor alpha | 2020 |
Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Bexarotene; Binding Sites; Cell Line, Tumor; Disease Models, Animal; Drug Discovery; Gene Expression; Humans; Mice; Models, Molecular; Molecular Conformation; Nuclear Receptor Subfamily 2, Group C, Member 2; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Protein Binding; Protein Transport; Signal Transduction; Structure-Activity Relationship; Transcription, Genetic; Xenograft Model Antitumor Assays | 2021 |